Corbus PharmaceuticalsCRBP
CRBP
About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Employees: 28
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
4.63% less ownership
Funds ownership: 89.92% [Q4 2024] → 85.29% (-4.63%) [Q1 2025]
13% less funds holding
Funds holding: 99 [Q4 2024] → 86 (-13) [Q1 2025]
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
56% less call options, than puts
Call options by funds: $58K | Put options by funds: $132K
57% less capital invested
Capital invested by funds: $129M [Q4 2024] → $55.4M (-$73.9M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$40
384%
upside
Avg. target
$51
521%
upside
High target
$58
601%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Brian Abrahams | 601%upside $58 | Outperform Maintained | 7 May 2025 |
Oppenheimer Jeff Jones | 577%upside $56 | Outperform Maintained | 7 May 2025 |
HC Wainwright & Co. Andres Maldonado | 384%upside $40 | Buy Maintained | 7 May 2025 |
Financial journalist opinion
Based on 3 articles about CRBP published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab).
Neutral
GlobeNewsWire
2 weeks ago
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will include presentations by key opinion leaders and fireside chats with companies developing obesity therapeutics. Piper Sandler clients can register for the event through their representative.
Neutral
Seeking Alpha
3 weeks ago
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?
CRBP's pipeline shows promise, especially CRB-701 with early signals of benefit and tolerability, but all programs remain in early clinical stages. The company's financial position is stable for now, with about two years of cash runway, but rising R&D costs could accelerate the need for funding. Market sentiment has become overly negative, valuing the pipeline at essentially zero after a steep drop unrelated to CRBP's own data.
Positive
Zacks Investment Research
1 month ago
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Neutral
GlobeNewsWire
1 month ago
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY.
Neutral
GlobeNewsWire
1 month ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
Neutral
Zacks Investment Research
1 month ago
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
Positive
Zacks Investment Research
2 months ago
3 Unconventional Cannabis Stocks to Watch in 2025
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 764.2% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
3 months ago
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the United States under an open IND.
Charts implemented using Lightweight Charts™